Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

Nature Medicine

Volumn 8, Issue 2, 2002, Pages 143-149

  Karpuj, Marcela V ^a   Becher, Mark W ^b   Springer, Joe E ^c   Chabas, Dorothee ^a   Youssef, Sawsan ^a   Pedotti, Rosetta ^a   Mitchell, Dennis ^a   Steinman, Lawrence ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTAMINE; HUNTINGTIN; POLYGLUTAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CROSS LINKING; DEATH; DEMENTIA; ENZYME INHIBITION; HUNTINGTON CHOREA; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; TRANSGENIC MOUSE; WEIGHT REDUCTION;

ANIMALS; BRAIN; CYSTAMINE; ENZYME INHIBITORS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MOVEMENT DISORDERS; SURVIVAL; TRANSGLUTAMINASES; WEIGHT LOSS;

ANIMALIA; MUS MUSCULUS;

EID: 0036172346     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0202-143     Document Type: Article

References (47)

1. Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism
2. Neurodegenerative diseases and transglutaminase
3. DRPLA aggregation and transglutaminase, revisited
4. Glutamine repeats and neurodegenerative diseases: Molecular aspects
5. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
6. Transglutaminase action imitates Huntington's disease: Selective polymerization of huntingtin containing expanded polyglutamine
7. Transglutaminase aggregates huntingtin into non-amyloidogenic polymers and its enzymatic activity is increased in Huntington's disease brain nuclei
8. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch
9. Neurodegenerative diseases and transglutaminase
10. Tissue transglutaminase is increased in Huntington's disease brain
11. Transglutaminases
12. Transglutaminases
13. Specificity of guinea pig liver transglutaminase for amine substrates
14. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
15. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
16. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
17. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
18. Intranuclear neuronal inclusions in Huntington's disease and DRPLA: Correlation between the density of inclusions and IT15 CAG triplet repeat length
19. Amyloid formation by mutant hutingtin: Threshold, progressivity, and recruitment of polyglutamine proteins
20. Transglutaminase catalyzed cross-links in intranuclear inclusions
21. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype
22. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
23. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
24. Reversing neurodegeneration: A promise unfolds
25. Nuclear inclusions in glutamine repeat disorders: Are they pernicious, coincidental or beneficial?
26. Transglutaminase: Mechanistic features of the active site as determined by kinetic and inhibitor studies
27. Fibrin-stabilizing factor (factor XIII)
28. Polyglutamine domains are substrates of tissue translutaminase: Does transglutaminase play a role in expanded CAG/poly Q neurodegenerative diseases?
29. Transgenic mice in the study of polyglutamine disease
30. Formation of polyglutamine inclusions in non-CNS tissue
31. + efflux and neuronal apoptosis
32. Substrate binding is required for assembly of the active conformation of the catalytic site in Ntn amidotransferases: Evidence from the 1.8 A crystal structure of the glutaminase domain of glucosamine 6-phosphate synthase
33. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease
34. Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death
35. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
36. Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis
37. Genetic suppression of polyglutamine toxicity in Drosophila
38. Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine
39. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract
40. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
41. The influence of the pro-inflammatory cytokine, osteopontin, on autoimmune demyelinating disease
42. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease
43. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
44. A one-hit model of cell death in inherited neuronal degenerations
45. N-(γ-L-glutamyl)-L-lysine is increased in cerebrospinal fluid of patients with Huntington's disease
46. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury
47. Detection of mouse osteopontin by western blotting